BioLine Rx licenses kidney drug

The treatment was invented by Professor Ariella Oppenheim of the Department of Hematology and Dr. Yosef Haviv of the Department of nephrology at Jerusalem's Hadassah University Hospital.

By JERUSALEM POST BUSINESS STAFF
August 28, 2007 07:58

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

BioLine Rx Ltd. announced Monday that it signed a worldwide, exclusive license agreement with Gene Vector Technologies Ltd. to develop and commercialize BL-4040, for the treatment of acute kidney injury. Financial terms were not disclosed. The treatment was invented by Professor Ariella Oppenheim of the Department of Hematology and Dr. Yosef Haviv of the Department of nephrology at Jerusalem's Hadassah University Hospital.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS